Table 4 of Park, Mol Vis 2014; 20:1680-1694.
Outcome parameters | Gene | Variant | Genotype (N)* | N (%) or Mean* | Genetic model | OR (95% CI)** | Uncorrected P - value† | Corrected P - value†† | |
---|---|---|---|---|---|---|---|---|---|
≥ 15-letter gain | 12mo | - | - | - | - | - | - | - | |
24mo | VEGFA | rs3025039 | CC(219) / CT(124) / TT(23) | 64(29.2) / 39(29.0) / 13(56.5) | Recessive | 4.57 (1.89-11.1) | 0.0027 | 0.0434 | |
BCVA change from baseline | 12mo | - | - | - | - | - | - | - | |
24mo | - | - | - | - | - | - | - | ||
Dry status on OCT | 12mo | - | - | - | - | - | - | - | |
24mo | - | - | - | - | - | - | - | ||
CSMT change from baseline | 12mo | ARMS2 | rs10490924 | TT(196) / TG(150) / GG(47) | -62.9 / -62.4 / -118.6 (µm) | Additive | - | 0.0141 | 0.2256 |
Recessive | - | 0.004 | 0.0656 | ||||||
HTRA1 | rs11200638 | AA(202) / AG(144) / GG(48) | -63.0 / -62.4 / -115.7 (µm) | Additive | - | 0.0141 | 0.2256 | ||
Recessive | - | 0.0033 | 0.0528 | ||||||
24mo | ARMS2 | rs10490924 | TT(183) / TG(139) / GG(44) | -63.2 / -60.9 / -126.2 (µm) | Additive | 0.0384 | 0.6144 | ||
Recessive | - | 0.0258 | 0.4128 | ||||||
HTRA1 | rs11200638 | AA(188) / AG(133) / GG(45) | -62.3 / -62.4 / -123.7 (µm) | Additive | - | 0.0323 | 0.5168 | ||
Recessive | - | 0.0293 | 0.4688 | ||||||
Number of injections | 12mo | ARMS2 | rs10490924 | TT(196) / TG(150) / GG(47) | 6.8 / 6.8 / 6.1 | Recessive | - | 0.0344 | 0.5504 |
HTRA1 | rs11200638 | AA(202) / AG(144) / GG(48) | 6.8 / 6.7 / 6.1 | Recessive | - | 0.0304 | 0.4864 | ||
24mo | VEGFA | rs3025039 | CC(219) / CT(124) / TT(23) | 10.7 / 10.4 / 9.0 | Additive | - | 0.0286 | 0.4576 | |
Recessive | - | 0.015 | 0.2352 | ||||||
ARMS2 | rs10490924 | TT(183) / TG(139) / GG(44) | 10.5 / 10.9 / 9.4 | Recessive | - | 0.0338 | 0.5408 | ||
HTRA1 | rs11200638 | AA(188) / AG(133) / GG(45) | 10.5 / 10.9 / 9.4 | Recessive | - | 0.0275 | 0.4403 |